Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Colorcon
Cantor Fitzgerald
Farmers Insurance
McKinsey
US Army

Generated: August 21, 2019

DrugPatentWatch Database Preview

Claims for Patent: 5,545,405

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,545,405
Title: Method for treating a mammal suffering from cancer with a cho-glycosylated antibody
Abstract:The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.
Inventor(s): Page; Martin J. (Beckenham, GB)
Assignee: Burroughs Wellcome Co. (Research Triangle Park, NC)
Application Number:08/335,401
Patent Claims:1. In a method for treating a human suffering from cancer by administering a therapeutically effective amount of a whole glycosylated recombinant human, chimeric, CDR grafted or bispecific antibody effective in treating said cancer, wherein the improvement comprises an antibody glycosylated by a Chinese hamster ovary cell.

2. A method in accordance with claim 1, wherein the cancer is non-Hodgkins lymphoma.

3. A method in accordance with claim 1, wherein the cancer is multiple myeloma.

4. A method in accordance with claim 3, wherein the antibody specifically recognizes a T cell marker.

5. A method in accordance with claim 4, wherein the antibody is an anti-CDw52 antibody.

6. A method in accordance with claim 1, wherein the antibody specifically recognizes a cancer cell marker antigen.

7. A method in accordance with claim 6, wherein the antibody is an anti-CD33 antibody or an anti-CD38 antibody.

8. A method in accordance with claim 1, wherein the antibody is administered in a daily dose of about 1 mg to about 10 mg.

9. A method in accordance with claim 1, wherein the antibody is administered for a period of about 1 to about 30 days.

Summary for Patent:   Try a Free Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9022543Oct 17, 1990

Details for Patent 5,545,405

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Try a Free Trial Burroughs Wellcome Co. (Research Triangle Park, NC) 2013-08-13 RX Orphan company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07   Try a Free Trial Burroughs Wellcome Co. (Research Triangle Park, NC) 2013-08-13 RX Orphan company
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Try a Free Trial Burroughs Wellcome Co. (Research Triangle Park, NC) 2013-08-13 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
AstraZeneca
QuintilesIMS
US Department of Justice
Covington
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.